Form 8-K · Current Report · Filed 2024-02-27
Apellis Pharmaceuticals Reports Q4 and FY 2023 Financial Results and Announces Capped Call Unwinding
Apellis Pharmaceuticals, Inc. reported its Q4 and full year 2023 financial results, highlighting significant revenue growth driven by SYFOVRE and EMPAVELI, despite reporting a net loss for the period. The company also announced the unwinding of a portion of its capped call transactions, expecting to receive approximately $100 million in net cash proceeds. The exhibit details the company's financial performance, business highlights, and forward-looking statements.
- Filer
- Apellis Pharmaceuticals Inc. APLS · NASDAQ
- Filed
- Accession
- 0001193125-24-047073
- CIK
- 0001492422
- Signal
- Low impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Results of Operations and Financial Condition
Other Events
Financial Statements and Exhibits
Market reaction
Close before filing
$6.41
Next session
-0.3%
Since filing
-46.9%
Latest close
$3.40
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from APLS reporting the same item, with the next session's move:
Exhibits (1)
About Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing novel therapeutic compounds to address complement-mediated diseases. The primary focus of Apellis is to pioneer medicines leveraging targeted inhibition of the complement system, a key component of the immune system that plays a crucial role in a variety of diseases. The company's flagship product, targeting diseases such as geographic atrophy and paroxysmal nocturnal hemoglobinuria (PNH), highlights its commitment to addressing unmet medical needs with innovative treatments. Apellis Pharmaceuticals operates in the highly competitive pharmaceutical and biotechnology industry, collaborating with healthcare providers and research institutions to advance clinical treatment options. Headquartered in Waltham, Massachusetts, its contributions to medical science are significant, paving the way for advancements in immunology and therapy development. As a publicly traded entity, Apellis influences the healthcare sector by enhancing treatment paradigms and offering new hope for patients with chronic and debilitating conditions.
Never miss another APLS filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.